Ozemback
Live tracker

Peptide legal status tracker: what is approved, what was only recommended, and what did not change

28 compounds, one row each. An advisory committee voted on seven peptides in July 2026 and the internet has been describing that vote as though it settled the law. It did not. This page states where each compound actually stands, and carries a date so you can tell when it stops being current.

On 30 October 2026 HHS published a draft enforcement discretion policy for the six peptides the committee recommended. It says HHS does not intend to act against 503A pharmacies and physicians compounding them under set conditions while FDA writes the 503A list rule. It is not binding, written comments run until 13 November 2026, and it puts none of the six on the list. Checked again on 12 November 2026: neither the Federal Register nor the HHS docket holds anything beyond that draft, so nothing about it is final.

Last updated 20 November 2026 · Votes verified against the committee record
ApprovedThe FDA has approved it for a stated use. Check which use.
Recommended, not lawAn advisory committee voted in favour in July 2026. The rulemaking that would make it real has not happened.
Recommended againstThe same committee voted it down.
NeitherNo approval, and not among the seven the committee reviewed. Nothing about it changed in July 2026.
CompoundStatusFDA approval July 2026 committee503A Bulks ListNote
SemaglutideOzempic, Wegovy Approved Approved Not applicable Not applicable An approved drug. The 503A compounding question does not apply to it.
TirzepatideMounjaro, Zepbound Approved Approved Not applicable Not applicable An approved drug. Dual GIP and GLP-1 receptor agonist.
LiraglutideSaxenda, Victoza Approved Approved Not applicable Not applicable Approved, and commercially in retreat as newer agents take the market.
OrforglipronFoundayo Approved Approved 1 April 2026 Not applicable Not applicable Approved as a new molecular entity under NDA 220934 and sold as Foundayo, an oral tablet. The label covers weight reduction and long-term maintenance in adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity, and says use with another GLP-1 agonist is not recommended (label effective 29 July 2026).
TesamorelinEgrifta Approved Approved since 2010 Not applicable Not applicable Approved for HIV-associated lipodystrophy only. The label says it is not for weight loss. Egrifta SV and Egrifta WR are not substitutable.
BPC-157Body Protection Compound 157 Recommended, not law Not approved In favour, 8 to 6 with 1 abstention Not on it. Removed from Category 2 on 15 April 2026. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list. No published randomised controlled trial in humans for any indication.
KPVLysine-proline-valine Recommended, not law Not approved In favour, 8 to 6 with 1 abstention, against FDA staff advice Not on it. Removed from Category 2 on 15 April 2026. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list; the draft covers KPV acetate in topical and oral forms only, not injections (BakerHostetler, FDA Law Blog, 28 October 2026). A tripeptide fragment of alpha-MSH. FDA found no study of KPV given to humans, by any route.
TB-500Thymosin beta-4 fragment Recommended, not law Not approved In favour, 8 to 6 with 1 abstention, against FDA staff advice Not on it. FDA lists the nomination as withdrawn. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list. A fragment of thymosin beta-4, not the same molecule. FDA found no published study of TB-500 given to humans.
MOTS-cMitochondrial ORF of the 12S rRNA type-c Recommended, not law Not approved In favour, 7 to 5 with 2 abstentions, against FDA staff advice Not on it. FDA lists the nomination as withdrawn. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list. A mitochondrial-derived peptide sold for weight loss. FDA found no study of it in humans by any route and no animal toxicity study. Two abstentions, the most of the six that passed.
EpitalonEpithalon, AEDG peptide Recommended, not law Not approved In favour, 7 to 4 with 1 abstention, against FDA staff advice Not on it. FDA lists the nomination as withdrawn. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list. Carries the largest longevity claims and the thinnest human evidence base. FDA found no clinical safety data and no study in people with insomnia.
SemaxACTH(4-10) analogue Recommended, not law Not approved In favour, 8 to 5 with 1 abstention, against FDA staff advice Not on it. FDA lists the nomination as withdrawn. Named in the HHS draft enforcement discretion policy published in the Federal Register on 30 October 2026, which is not binding and does not add it to the 503A list. Registered as a medicine in Russia. That is not an FDA approval. FDA found no human pharmacokinetic study by any route.
EmideltideDSIP, delta sleep-inducing peptide Recommended against Not approved Against, 6 to 7 Not on it, and recommended against. The only one of the seven the committee voted down.
SermorelinGeref Neither Formerly approved as Geref. No approved product today. Not among the seven reviewed Not on it, and not in the interim categories. Discontinued by the manufacturer in 2008. Compounded today under a different pathway.
CJC-1295 Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA cites reported serious adverse events, including increased heart rate and a systemic vasodilatory reaction (FDA safety-risk page, current as of 22 April 2026).
Ipamorelin Neither Not approved Not among the seven reviewed Not on it. 503A nomination withdrawn; still in 503B Category 2 since 29 September 2023. An FDA advisory committee voted against adding it to the 503A Bulks List on 29 October 2024, 0 for, 12 against, 1 abstention (FDA minutes). FDA cites a published report of serious adverse events, including death, after intravenous use (FDA safety-risk page, current as of 22 April 2026).
GHK-CuCopper peptide Neither Not approved as a drug Not among the seven reviewed Not on it. Removed from interim Category 1 on 22 April 2026 because the nominations were withdrawn. On 5 May 2026 one nominator clarified it had withdrawn only the injectable route, so GHK-Cu except injectable routes is being added back to Category 1. Injectable GHK-Cu is listed by FDA among substances previously in Category 2 whose nominations were withdrawn (FDA safety-risk page, current as of 22 April 2026). Widely sold in cosmetics, which is a different regulatory category entirely. FDA says it intends to consult the compounding committee about GHK-Cu before the end of February 2027 (FDA list of nominated substances, updated 14 May 2026).
5-Amino-1MQ Neither Not approved Not among the seven reviewed Not on it. Not reviewed by the committee and absent from the FDA Category 2 page. Its status did not move in 2026.
Melanotan II Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA cites published case reports of serious adverse events, including melanoma (FDA safety-risk page, current as of 22 April 2026).
AOD-9604hGH fragment 177-191 analogue Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA says it has no, or only limited, safety information, and has identified serious adverse events that may be associated with it, causality unclear (FDA safety-risk page, current as of 22 April 2026).
Cathelicidin LL-37LL-37 Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA says it lacks enough safety information to know whether it would cause harm in humans (FDA safety-risk page, current as of 22 April 2026).
DihexaDihexa acetate Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA found no human exposure data for any route of administration (FDA safety-risk page, current as of 22 April 2026).
PEG-MGFPegylated mechano growth factor Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. FDA found no human exposure data for any route of administration (FDA safety-risk page, current as of 22 April 2026).
SelankSelank acetate, TP-7 Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. Often paired with Semax online, but it was not part of the July 2026 review (FDA safety-risk page, current as of 22 April 2026).
Thymosin alpha-1Ta1, thymalfasin Neither Not approved Not among the seven reviewed Not on it. Nomination withdrawn from the interim Category 2. Not the same molecule as thymosin beta-4 or TB-500. FDA calls its safety information inadequate (FDA safety-risk page, current as of 22 April 2026).
Kisspeptin-10 Neither Not approved Not among the seven reviewed Not on it. In 503A Category 2, flagged as a possible safety risk, since 29 September 2023. An FDA advisory committee voted against adding it to the 503A Bulks List on 29 October 2024, 0 for, 11 against (FDA minutes). Unlike most peptides on this page, it is still in Category 2 (FDA safety-risk page, current as of 22 April 2026).
GHRP-2Growth hormone releasing peptide-2 Neither Not approved Not among the seven reviewed Not on it. In 503B Category 2 (injectable and nasal) since 29 September 2023. FDA cites reports of serious adverse events, including increased insulin requirement (FDA safety-risk page, current as of 22 April 2026).
GHRP-6Growth hormone releasing peptide-6 Neither Not approved Not among the seven reviewed Not on it. In 503B Category 2 since 29 September 2023. FDA cites possible effects on cortisol and higher blood glucose from reduced insulin sensitivity (FDA safety-risk page, current as of 22 April 2026).
IbutamorenMK-677, ibutamoren mesylate Neither Not approved Not among the seven reviewed Not on it. In Category 2 for both 503A (29 September 2023) and 503B (29 December 2022). An FDA advisory committee voted against adding it to the 503A Bulks List on 29 October 2024, 1 for, 13 against (FDA minutes). Sold alongside peptides but it is not one. FDA cites a hip fracture trial terminated early for a possible congestive heart failure signal (FDA safety-risk page, current as of 22 April 2026).

Sources. Category 2 and withdrawn nominations: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of 22 April 2026. 503A Bulks List: FDA, Bulk drug substances used in compounding under section 503A, and the interim categories in FDA, Bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026. Approval dates and label wording: Drugs@FDA. Enforcement discretion: HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192, docket HHS-OASH-2026-0496, published 30 October 2026. A withdrawn nomination is not an approval and does not place a substance on the 503A list.

Get told when a status on this page changes

This table only matters because it is current. When the FDA opens rulemaking, publishes a rule, or a committee votes again, this page changes that day and you get one email saying exactly which row moved and why. Nothing else.

Only when something actually changes. Unsubscribe in one click.
How to read this table, and how not to

Every column here is regulatory. A compound appearing as recommended means a committee voted for it to be available for pharmacy compounding. It does not mean the compound is safe, that it works, or that it is appropriate for anyone in particular. Those are separate questions and this table does not answer them.

Nothing on this page is medical advice or a recommendation to take or avoid anything. Ozemback is an independent publication, not a provider, and takes no part in any clinical decision. Talk to a licensed clinician. See the full terms and editorial disclaimer.

Test yourself

Most people get this wrong, and they get it wrong in the same direction: they assume the July vote made these legal. Ten compounds, one question each.

Take the quiz →

Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer